CN107106562B - 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗 - Google Patents

使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗 Download PDF

Info

Publication number
CN107106562B
CN107106562B CN201580068262.4A CN201580068262A CN107106562B CN 107106562 B CN107106562 B CN 107106562B CN 201580068262 A CN201580068262 A CN 201580068262A CN 107106562 B CN107106562 B CN 107106562B
Authority
CN
China
Prior art keywords
receptor
liver
liver disease
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580068262.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107106562A (zh
Inventor
J·K·贝拉诺夫
H·亨特
O·C·梅杰
J·范登霍伊维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Priority to CN202010597452.8A priority Critical patent/CN111557942B/zh
Publication of CN107106562A publication Critical patent/CN107106562A/zh
Application granted granted Critical
Publication of CN107106562B publication Critical patent/CN107106562B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580068262.4A 2014-10-15 2015-10-14 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗 Active CN107106562B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010597452.8A CN111557942B (zh) 2014-10-15 2015-10-14 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010597452.8A Division CN111557942B (zh) 2014-10-15 2015-10-14 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗

Publications (2)

Publication Number Publication Date
CN107106562A CN107106562A (zh) 2017-08-29
CN107106562B true CN107106562B (zh) 2020-08-18

Family

ID=55747256

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010597452.8A Active CN111557942B (zh) 2014-10-15 2015-10-14 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗
CN201580068262.4A Active CN107106562B (zh) 2014-10-15 2015-10-14 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010597452.8A Active CN111557942B (zh) 2014-10-15 2015-10-14 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP4353310A3 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN111557942B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3206692T (pt) 2014-10-15 2024-04-30 Corcept Therapeutics Inc Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides
JP7196201B2 (ja) * 2018-06-04 2022-12-26 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
KR20210153056A (ko) 2019-03-18 2021-12-16 리네트 케이. 니만 인슐린 감수성 개선 방법
AU2021266739B2 (en) * 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3182272A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
KR20230124020A (ko) 2020-12-21 2023-08-24 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 시클로헥실 글루코코르티코이드 수용체 조절제의제조 방법
AU2022271209A1 (en) * 2021-05-05 2023-11-09 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101313066A (zh) * 2005-09-19 2008-11-26 强生医药研究及开发有限责任公司 糖皮质激素受体表达的调节
CN103596431A (zh) * 2011-03-18 2014-02-19 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
US7745657B2 (en) 2005-05-18 2010-06-29 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
MX2009011062A (es) 2007-04-13 2009-10-29 Schering Corp Derivados de pirimidindiona y sus metodos de uso.
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
PT3206692T (pt) 2014-10-15 2024-04-30 Corcept Therapeutics Inc Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101313066A (zh) * 2005-09-19 2008-11-26 强生医药研究及开发有限责任公司 糖皮质激素受体表达的调节
CN103596431A (zh) * 2011-03-18 2014-02-19 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat;Hazel J. Hunt等;《Bioorganic & Medicinal Chemistry Letters》;20121023;第22卷;第7376-7380页 *
Histological Evaluation of the Role of Atypical Antipsychotic Drugs in Inducing Non-Alcoholic Fatty Liver Disease in Adult Male Albino Rats (Light and Electron Microscopic Study);H. M. SOLIMAN等;《Folia Biologica》;20131231;第59卷;第173-180页 *

Also Published As

Publication number Publication date
UA123537C2 (uk) 2021-04-21
NZ731060A (en) 2023-07-28
KR102435956B1 (ko) 2022-08-23
EP3206692A1 (en) 2017-08-23
MX2017004943A (es) 2017-07-19
RU2718921C2 (ru) 2020-04-15
DK3206692T3 (da) 2024-04-29
ES2978871T3 (es) 2024-09-23
RU2017114596A3 (enExample) 2019-05-08
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
US10238659B2 (en) 2019-03-26
JP6761410B2 (ja) 2020-09-23
JP2017531013A (ja) 2017-10-19
ZA201702813B (en) 2019-05-29
AU2015333645A1 (en) 2017-05-04
US10881660B2 (en) 2021-01-05
EP3206692B1 (en) 2024-04-03
EP4353310A3 (en) 2024-06-19
FI3206692T3 (fi) 2024-05-06
BR112017007860B1 (pt) 2023-03-07
IL251729A0 (en) 2017-06-29
US20230218621A1 (en) 2023-07-13
CA2964625C (en) 2023-03-07
US20160106749A1 (en) 2016-04-21
US20190151318A1 (en) 2019-05-23
AU2015333645B2 (en) 2020-01-30
KR20170066646A (ko) 2017-06-14
PH12017500710A1 (en) 2017-10-09
RU2017114596A (ru) 2018-11-15
PL3206692T3 (pl) 2024-07-22
PH12017500710B1 (en) 2024-01-17
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
SG11201703024VA (en) 2017-05-30
US11590135B2 (en) 2023-02-28
EP3206692A4 (en) 2018-05-30
CA2964625A1 (en) 2016-04-21
CN111557942A (zh) 2020-08-21
US20210085682A1 (en) 2021-03-25
IL251729B (en) 2020-03-31
WO2016061195A1 (en) 2016-04-21
US12226417B2 (en) 2025-02-18
BR112017007860A2 (pt) 2018-01-16
EP4353310A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
CN107106562B (zh) 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗
Wong et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease
US11073523B2 (en) Method for differentially diagnosing ACTH-dependent Cushing's syndrome
JP6821582B2 (ja) Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
US8486926B2 (en) Steroid tetrol solid state forms
JP2023524780A (ja) ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの多形
AU2021220763A1 (en) Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator
HK40102771A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
TW201211041A (en) Agent for preventing or treating nonalcoholic steatohepatitis
HK1240087B (zh) 使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療
HK1240087A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
JP5211322B2 (ja) ピリミジン−５−カルボン酸誘導体の抗肥満剤としての新規用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240087

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant